| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Aneurysm | 25 | 2024 | 178 | 5.030 |
Why?
|
| Embolization, Therapeutic | 29 | 2024 | 265 | 4.210 |
Why?
|
| Thrombectomy | 14 | 2024 | 190 | 3.770 |
Why?
|
| Intracranial Arteriovenous Malformations | 15 | 2024 | 110 | 3.420 |
Why?
|
| Angiography, Digital Subtraction | 17 | 2024 | 99 | 3.410 |
Why?
|
| Cerebral Angiography | 25 | 2019 | 197 | 3.330 |
Why?
|
| Stents | 23 | 2022 | 412 | 3.330 |
Why?
|
| Endovascular Procedures | 24 | 2024 | 290 | 3.240 |
Why?
|
| Stroke | 24 | 2024 | 994 | 3.020 |
Why?
|
| Magnetic Resonance Angiography | 19 | 2024 | 275 | 2.880 |
Why?
|
| Cerebrovascular Disorders | 10 | 2019 | 145 | 2.440 |
Why?
|
| Intracranial Arteriosclerosis | 8 | 2024 | 55 | 2.430 |
Why?
|
| Brain Ischemia | 10 | 2023 | 400 | 2.240 |
Why?
|
| Cerebrovascular Circulation | 12 | 2024 | 232 | 1.930 |
Why?
|
| Imaging, Three-Dimensional | 12 | 2024 | 602 | 1.700 |
Why?
|
| Neuroimaging | 6 | 2019 | 116 | 1.660 |
Why?
|
| Magnetic Resonance Imaging | 19 | 2024 | 3480 | 1.560 |
Why?
|
| Arteriovenous Fistula | 8 | 2016 | 53 | 1.550 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2024 | 60 | 1.410 |
Why?
|
| Computed Tomography Angiography | 4 | 2018 | 155 | 1.150 |
Why?
|
| Retrospective Studies | 36 | 2024 | 9259 | 1.070 |
Why?
|
| Surgery, Computer-Assisted | 4 | 2018 | 99 | 1.070 |
Why?
|
| Treatment Outcome | 42 | 2024 | 8313 | 1.070 |
Why?
|
| Middle Aged | 56 | 2024 | 26195 | 1.050 |
Why?
|
| Humans | 135 | 2024 | 90071 | 1.050 |
Why?
|
| Contrast Media | 9 | 2024 | 1083 | 1.040 |
Why?
|
| Male | 79 | 2024 | 42741 | 1.030 |
Why?
|
| Aged | 44 | 2024 | 19282 | 1.020 |
Why?
|
| Reperfusion | 4 | 2020 | 32 | 1.020 |
Why?
|
| Carotid Artery Diseases | 4 | 2019 | 99 | 1.020 |
Why?
|
| Polyvinyls | 5 | 2013 | 17 | 1.020 |
Why?
|
| Infarction, Middle Cerebral Artery | 3 | 2020 | 40 | 0.990 |
Why?
|
| Female | 76 | 2024 | 46656 | 0.950 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2024 | 2675 | 0.920 |
Why?
|
| Vasculitis | 1 | 2024 | 40 | 0.910 |
Why?
|
| Aneurysm, Ruptured | 9 | 2024 | 54 | 0.870 |
Why?
|
| Blood Vessel Prosthesis | 7 | 2021 | 244 | 0.840 |
Why?
|
| Vasospasm, Intracranial | 3 | 2011 | 35 | 0.830 |
Why?
|
| Hemodynamics | 7 | 2023 | 738 | 0.800 |
Why?
|
| Catheterization | 3 | 2019 | 237 | 0.780 |
Why?
|
| Arteriovenous Malformations | 2 | 2013 | 45 | 0.760 |
Why?
|
| After-Hours Care | 1 | 2021 | 8 | 0.740 |
Why?
|
| Atherosclerosis | 1 | 2024 | 259 | 0.730 |
Why?
|
| Adult | 44 | 2024 | 26855 | 0.730 |
Why?
|
| Neurosurgical Procedures | 7 | 2021 | 243 | 0.710 |
Why?
|
| Cerebral Arteries | 6 | 2017 | 74 | 0.690 |
Why?
|
| Time-to-Treatment | 2 | 2021 | 124 | 0.690 |
Why?
|
| Intracranial Hemorrhages | 2 | 2018 | 130 | 0.680 |
Why?
|
| Radiography, Interventional | 3 | 2010 | 157 | 0.680 |
Why?
|
| Vertebral Artery | 3 | 2016 | 24 | 0.650 |
Why?
|
| Registries | 5 | 2024 | 809 | 0.640 |
Why?
|
| Neutrophils | 1 | 2020 | 312 | 0.630 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2021 | 147 | 0.620 |
Why?
|
| Lymphocytes | 1 | 2020 | 468 | 0.610 |
Why?
|
| Polymers | 2 | 2021 | 196 | 0.610 |
Why?
|
| Catheters | 1 | 2018 | 85 | 0.590 |
Why?
|
| Aneurysm, False | 2 | 2024 | 55 | 0.580 |
Why?
|
| Carotid Stenosis | 4 | 2022 | 117 | 0.570 |
Why?
|
| Gadolinium | 2 | 2016 | 103 | 0.550 |
Why?
|
| Carotid Artery, Internal | 3 | 2016 | 69 | 0.550 |
Why?
|
| Sensitivity and Specificity | 12 | 2019 | 2019 | 0.550 |
Why?
|
| Carotid Artery, Internal, Dissection | 3 | 2014 | 23 | 0.540 |
Why?
|
| Reproducibility of Results | 14 | 2024 | 2770 | 0.530 |
Why?
|
| Spinal Cord | 3 | 2014 | 255 | 0.530 |
Why?
|
| Subarachnoid Hemorrhage | 4 | 2020 | 142 | 0.530 |
Why?
|
| Pseudotumor Cerebri | 1 | 2016 | 17 | 0.520 |
Why?
|
| Head and Neck Neoplasms | 4 | 2011 | 1059 | 0.520 |
Why?
|
| Aged, 80 and over | 15 | 2024 | 6786 | 0.520 |
Why?
|
| Radiation Exposure | 1 | 2016 | 25 | 0.520 |
Why?
|
| Tinnitus | 1 | 2016 | 21 | 0.510 |
Why?
|
| Radiation Dosage | 2 | 2016 | 231 | 0.510 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2015 | 19 | 0.510 |
Why?
|
| Perfusion Imaging | 2 | 2018 | 50 | 0.510 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 163 | 0.510 |
Why?
|
| Brain | 8 | 2023 | 2310 | 0.490 |
Why?
|
| Radiosurgery | 4 | 2024 | 286 | 0.490 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2017 | 64 | 0.470 |
Why?
|
| Cerebral Revascularization | 2 | 2014 | 28 | 0.470 |
Why?
|
| Burnout, Professional | 3 | 2022 | 102 | 0.470 |
Why?
|
| Vascular Surgical Procedures | 3 | 2009 | 149 | 0.440 |
Why?
|
| Cranial Sinuses | 3 | 2021 | 15 | 0.430 |
Why?
|
| Physicians | 5 | 2022 | 692 | 0.430 |
Why?
|
| Microsurgery | 3 | 2024 | 91 | 0.420 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.420 |
Why?
|
| Vertebral Artery Dissection | 2 | 2014 | 14 | 0.420 |
Why?
|
| Image Enhancement | 5 | 2019 | 565 | 0.400 |
Why?
|
| Endarterectomy, Carotid | 2 | 2022 | 74 | 0.380 |
Why?
|
| Carotid Body Tumor | 1 | 2011 | 3 | 0.380 |
Why?
|
| Risk Factors | 10 | 2022 | 5574 | 0.380 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 13 | 0.370 |
Why?
|
| Fibrinolytic Agents | 5 | 2018 | 227 | 0.370 |
Why?
|
| Cocaine-Related Disorders | 1 | 2011 | 35 | 0.360 |
Why?
|
| Algorithms | 5 | 2024 | 1912 | 0.360 |
Why?
|
| Young Adult | 11 | 2024 | 6424 | 0.350 |
Why?
|
| Hydroxyapatites | 1 | 2010 | 7 | 0.350 |
Why?
|
| Molar | 1 | 2010 | 22 | 0.350 |
Why?
|
| Blood Flow Velocity | 8 | 2023 | 199 | 0.350 |
Why?
|
| Oral Surgical Procedures | 1 | 2010 | 19 | 0.350 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 25 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 1056 | 0.340 |
Why?
|
| Hemorrhage | 2 | 2014 | 287 | 0.340 |
Why?
|
| Carotid Artery Injuries | 1 | 2010 | 22 | 0.340 |
Why?
|
| Diagnosis, Differential | 7 | 2015 | 1604 | 0.330 |
Why?
|
| Central Nervous System Vascular Malformations | 4 | 2018 | 33 | 0.330 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 3689 | 0.330 |
Why?
|
| Job Satisfaction | 2 | 2020 | 79 | 0.320 |
Why?
|
| Intracranial Thrombosis | 2 | 2018 | 29 | 0.320 |
Why?
|
| Mandible | 1 | 2010 | 121 | 0.320 |
Why?
|
| Collateral Circulation | 2 | 2020 | 37 | 0.310 |
Why?
|
| Prospective Studies | 8 | 2023 | 4333 | 0.310 |
Why?
|
| Postoperative Complications | 7 | 2023 | 2323 | 0.310 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2021 | 227 | 0.310 |
Why?
|
| Research Report | 2 | 2021 | 44 | 0.300 |
Why?
|
| Image Interpretation, Computer-Assisted | 5 | 2024 | 695 | 0.300 |
Why?
|
| Angioplasty | 3 | 2021 | 70 | 0.300 |
Why?
|
| Pilot Projects | 6 | 2023 | 872 | 0.300 |
Why?
|
| Dimethyl Sulfoxide | 3 | 2013 | 38 | 0.300 |
Why?
|
| Adolescent | 13 | 2021 | 9363 | 0.290 |
Why?
|
| Anticoagulants | 3 | 2024 | 434 | 0.290 |
Why?
|
| Eye Diseases | 2 | 2005 | 59 | 0.290 |
Why?
|
| Surgical Flaps | 1 | 2010 | 250 | 0.290 |
Why?
|
| Diagnostic Imaging | 3 | 2009 | 475 | 0.290 |
Why?
|
| Hand | 5 | 1991 | 143 | 0.280 |
Why?
|
| Single-Blind Method | 3 | 2018 | 152 | 0.280 |
Why?
|
| Prevalence | 4 | 2021 | 1250 | 0.280 |
Why?
|
| Cerebral Veins | 3 | 2016 | 31 | 0.270 |
Why?
|
| Pandemics | 3 | 2021 | 778 | 0.270 |
Why?
|
| Rotavirus | 3 | 1991 | 11 | 0.260 |
Why?
|
| Risk Assessment | 6 | 2022 | 2329 | 0.260 |
Why?
|
| Neurosurgery | 3 | 2020 | 105 | 0.260 |
Why?
|
| Societies, Medical | 3 | 2021 | 584 | 0.260 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2017 | 18 | 0.250 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 2005 | 2 | 0.250 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 3 | 2009 | 4 | 0.250 |
Why?
|
| Orbital Neoplasms | 1 | 2005 | 17 | 0.250 |
Why?
|
| Lacrimal Apparatus | 1 | 2005 | 11 | 0.240 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 27 | 0.240 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.240 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 305 | 0.240 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 2658 | 0.240 |
Why?
|
| Gadolinium DTPA | 2 | 2024 | 256 | 0.240 |
Why?
|
| Hirudins | 1 | 2024 | 5 | 0.230 |
Why?
|
| Hemangioma, Cavernous | 1 | 2005 | 69 | 0.230 |
Why?
|
| Eye | 1 | 2005 | 111 | 0.230 |
Why?
|
| Radiology, Interventional | 3 | 2009 | 69 | 0.230 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2020 | 300 | 0.230 |
Why?
|
| Antithrombins | 1 | 2024 | 16 | 0.230 |
Why?
|
| Multimorbidity | 1 | 2024 | 5 | 0.230 |
Why?
|
| Fatal Outcome | 2 | 2016 | 296 | 0.230 |
Why?
|
| National Health Programs | 1 | 2024 | 19 | 0.230 |
Why?
|
| Medicare | 2 | 2018 | 427 | 0.220 |
Why?
|
| Treatment Failure | 2 | 2021 | 279 | 0.220 |
Why?
|
| Heparin | 1 | 2024 | 184 | 0.220 |
Why?
|
| Propensity Score | 1 | 2023 | 151 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 186 | 0.210 |
Why?
|
| Phantoms, Imaging | 4 | 2019 | 463 | 0.210 |
Why?
|
| Artifacts | 4 | 2013 | 246 | 0.210 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2015 | 142 | 0.200 |
Why?
|
| Elective Surgical Procedures | 2 | 2021 | 130 | 0.200 |
Why?
|
| Delivery of Health Care | 3 | 2024 | 437 | 0.200 |
Why?
|
| Time Factors | 7 | 2021 | 5364 | 0.200 |
Why?
|
| United States | 12 | 2024 | 7118 | 0.200 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 1008 | 0.200 |
Why?
|
| Peptide Fragments | 1 | 2024 | 463 | 0.200 |
Why?
|
| Carotid Arteries | 2 | 2021 | 135 | 0.190 |
Why?
|
| Cohort Studies | 9 | 2023 | 2891 | 0.190 |
Why?
|
| Regional Blood Flow | 2 | 2019 | 198 | 0.190 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2021 | 11 | 0.190 |
Why?
|
| Child | 10 | 2021 | 7257 | 0.190 |
Why?
|
| Embolic Protection Devices | 1 | 2021 | 9 | 0.190 |
Why?
|
| Embolism | 1 | 2021 | 32 | 0.180 |
Why?
|
| Hospitals, Community | 1 | 2021 | 32 | 0.180 |
Why?
|
| Neurosurgeons | 1 | 2021 | 37 | 0.180 |
Why?
|
| Hand Disinfection | 2 | 1991 | 17 | 0.180 |
Why?
|
| Hydralazine | 1 | 2020 | 19 | 0.180 |
Why?
|
| North America | 1 | 2021 | 188 | 0.180 |
Why?
|
| Spinal Cord Ischemia | 1 | 2020 | 8 | 0.180 |
Why?
|
| Neck | 2 | 2013 | 104 | 0.180 |
Why?
|
| Acute Disease | 2 | 2014 | 850 | 0.180 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2024 | 1253 | 0.180 |
Why?
|
| Observer Variation | 4 | 2016 | 614 | 0.180 |
Why?
|
| Patient Readmission | 2 | 2022 | 355 | 0.180 |
Why?
|
| Thoracic Vertebrae | 1 | 2020 | 51 | 0.180 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 385 | 0.180 |
Why?
|
| Basilar Artery | 1 | 2020 | 42 | 0.170 |
Why?
|
| Emergencies | 1 | 2021 | 122 | 0.170 |
Why?
|
| Conservative Treatment | 1 | 2020 | 21 | 0.170 |
Why?
|
| Norepinephrine | 1 | 2020 | 172 | 0.170 |
Why?
|
| Thrombolytic Therapy | 2 | 2021 | 241 | 0.170 |
Why?
|
| Permeability | 2 | 2017 | 138 | 0.170 |
Why?
|
| Hydrogels | 1 | 2020 | 87 | 0.170 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 29 | 0.170 |
Why?
|
| Lumbar Vertebrae | 1 | 2020 | 152 | 0.160 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 67 | 0.160 |
Why?
|
| Health Expenditures | 2 | 2018 | 90 | 0.160 |
Why?
|
| Computer Graphics | 1 | 2019 | 100 | 0.160 |
Why?
|
| Social Media | 1 | 2021 | 96 | 0.160 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2013 | 259 | 0.160 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2011 | 30 | 0.160 |
Why?
|
| Embolectomy | 2 | 2015 | 6 | 0.160 |
Why?
|
| Physician's Role | 1 | 2020 | 176 | 0.160 |
Why?
|
| Preoperative Care | 2 | 2012 | 396 | 0.160 |
Why?
|
| Angiography | 3 | 2020 | 208 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 785 | 0.150 |
Why?
|
| Multimodal Imaging | 2 | 2017 | 112 | 0.150 |
Why?
|
| Vascular Closure Devices | 1 | 2018 | 3 | 0.150 |
Why?
|
| Chicago | 2 | 2021 | 1434 | 0.150 |
Why?
|
| Spinal Diseases | 2 | 2020 | 44 | 0.150 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1731 | 0.150 |
Why?
|
| Neuroendoscopy | 1 | 2018 | 18 | 0.150 |
Why?
|
| Disease Management | 2 | 2017 | 328 | 0.150 |
Why?
|
| Intracranial Hypertension | 2 | 2016 | 58 | 0.150 |
Why?
|
| Health Personnel | 1 | 2020 | 214 | 0.150 |
Why?
|
| Escherichia coli | 2 | 1991 | 607 | 0.150 |
Why?
|
| Foreign Bodies | 1 | 2018 | 66 | 0.140 |
Why?
|
| Neurovascular Coupling | 1 | 2017 | 2 | 0.140 |
Why?
|
| Thrombosis | 1 | 2020 | 302 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 60 | 0.140 |
Why?
|
| Pia Mater | 1 | 2016 | 5 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.140 |
Why?
|
| Glioblastoma | 1 | 2019 | 266 | 0.140 |
Why?
|
| Patient Selection | 3 | 2021 | 682 | 0.130 |
Why?
|
| Superior Sagittal Sinus | 1 | 2016 | 2 | 0.130 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 72 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 415 | 0.130 |
Why?
|
| Arteriosclerosis | 1 | 2016 | 112 | 0.130 |
Why?
|
| Veins | 1 | 2016 | 95 | 0.130 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2016 | 67 | 0.130 |
Why?
|
| Databases, Factual | 4 | 2023 | 870 | 0.130 |
Why?
|
| Coronary Circulation | 1 | 2016 | 131 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1706 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 654 | 0.120 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 782 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1871 | 0.120 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 11 | 0.120 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2015 | 110 | 0.110 |
Why?
|
| Thromboembolism | 2 | 2014 | 122 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2016 | 258 | 0.110 |
Why?
|
| Capillary Permeability | 1 | 2015 | 132 | 0.110 |
Why?
|
| Radiography | 2 | 2013 | 809 | 0.110 |
Why?
|
| Hoarseness | 1 | 2013 | 11 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 493 | 0.110 |
Why?
|
| Biomarkers | 1 | 2020 | 1780 | 0.110 |
Why?
|
| Vocal Cord Paralysis | 1 | 2013 | 27 | 0.110 |
Why?
|
| Syndrome | 2 | 2011 | 450 | 0.110 |
Why?
|
| Moyamoya Disease | 1 | 2013 | 15 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 377 | 0.110 |
Why?
|
| Platinum | 2 | 2020 | 64 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2015 | 173 | 0.110 |
Why?
|
| Fistula | 1 | 2013 | 42 | 0.110 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 465 | 0.110 |
Why?
|
| Vertebroplasty | 1 | 2013 | 8 | 0.110 |
Why?
|
| Needles | 1 | 2013 | 40 | 0.100 |
Why?
|
| Ventriculostomy | 1 | 2013 | 29 | 0.100 |
Why?
|
| Competency-Based Education | 1 | 2013 | 38 | 0.100 |
Why?
|
| Aortic Coarctation | 1 | 2012 | 36 | 0.100 |
Why?
|
| Illinois | 1 | 2014 | 485 | 0.100 |
Why?
|
| Astrocytoma | 1 | 2012 | 82 | 0.100 |
Why?
|
| Paramyxoviridae Infections | 1 | 1991 | 5 | 0.100 |
Why?
|
| Common Cold | 1 | 1991 | 13 | 0.100 |
Why?
|
| Disinfection | 1 | 1991 | 15 | 0.100 |
Why?
|
| Rotavirus Infections | 1 | 1991 | 12 | 0.090 |
Why?
|
| Hemostasis | 1 | 2011 | 21 | 0.090 |
Why?
|
| Gastroenteritis | 1 | 1991 | 26 | 0.090 |
Why?
|
| Injections | 1 | 2011 | 116 | 0.090 |
Why?
|
| Length of Stay | 3 | 2015 | 753 | 0.090 |
Why?
|
| Aging | 1 | 2016 | 727 | 0.090 |
Why?
|
| Iatrogenic Disease | 1 | 2011 | 70 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2011 | 126 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 1991 | 107 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1735 | 0.090 |
Why?
|
| Injections, Intralesional | 1 | 2010 | 22 | 0.090 |
Why?
|
| Headache | 1 | 2011 | 74 | 0.090 |
Why?
|
| Alveolar Bone Loss | 1 | 2010 | 20 | 0.090 |
Why?
|
| Postpartum Period | 1 | 2011 | 153 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 1991 | 156 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2021 | 3781 | 0.090 |
Why?
|
| Recurrence | 3 | 2020 | 1150 | 0.080 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1989 | 24 | 0.080 |
Why?
|
| Survival Rate | 1 | 2014 | 1901 | 0.080 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2009 | 7 | 0.080 |
Why?
|
| Hospitalization | 1 | 2015 | 889 | 0.080 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 2009 | 3 | 0.080 |
Why?
|
| Hemostatics | 1 | 2009 | 58 | 0.080 |
Why?
|
| Iohexol | 1 | 2009 | 24 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2010 | 186 | 0.080 |
Why?
|
| Cerebrovascular Trauma | 1 | 2009 | 8 | 0.080 |
Why?
|
| Neuroradiography | 1 | 2008 | 3 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2009 | 234 | 0.080 |
Why?
|
| Incidence | 3 | 2020 | 1607 | 0.080 |
Why?
|
| Hyperthermia, Induced | 1 | 2009 | 73 | 0.080 |
Why?
|
| Equipment Contamination | 1 | 1988 | 25 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1474 | 0.080 |
Why?
|
| Infant | 4 | 2016 | 3197 | 0.080 |
Why?
|
| Critical Illness | 1 | 2011 | 312 | 0.080 |
Why?
|
| Mass Screening | 1 | 2013 | 649 | 0.070 |
Why?
|
| Hospital Mortality | 3 | 2021 | 410 | 0.070 |
Why?
|
| Anesthesia | 1 | 2010 | 169 | 0.070 |
Why?
|
| Head | 1 | 2008 | 136 | 0.070 |
Why?
|
| Anesthesiology | 1 | 2010 | 157 | 0.070 |
Why?
|
| Dogs | 2 | 2020 | 706 | 0.070 |
Why?
|
| Cerebral Hemorrhage | 1 | 2010 | 341 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1869 | 0.070 |
Why?
|
| Brain Injuries | 1 | 2009 | 166 | 0.070 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2006 | 31 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 530 | 0.060 |
Why?
|
| Inpatients | 2 | 2022 | 312 | 0.060 |
Why?
|
| Aneurysm | 2 | 2017 | 60 | 0.060 |
Why?
|
| ROC Curve | 2 | 2019 | 778 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2006 | 236 | 0.060 |
Why?
|
| Neurologic Examination | 2 | 2016 | 120 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2024 | 27 | 0.060 |
Why?
|
| Healthy Volunteers | 1 | 2024 | 146 | 0.060 |
Why?
|
| Australia | 1 | 2024 | 101 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1215 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2500 | 0.050 |
Why?
|
| Spine | 2 | 2013 | 102 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 168 | 0.050 |
Why?
|
| Equipment Design | 2 | 2018 | 422 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2015 | 788 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 174 | 0.050 |
Why?
|
| Medical Errors | 1 | 2022 | 115 | 0.050 |
Why?
|
| Accidents, Traffic | 1 | 2022 | 98 | 0.050 |
Why?
|
| Sleep Deprivation | 1 | 2022 | 138 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 262 | 0.050 |
Why?
|
| Infarction | 1 | 2020 | 27 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2017 | 1102 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 960 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2020 | 56 | 0.040 |
Why?
|
| Retreatment | 1 | 2020 | 107 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2020 | 145 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 76 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1879 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 114 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2019 | 64 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 745 | 0.040 |
Why?
|
| Calcinosis | 1 | 2019 | 230 | 0.040 |
Why?
|
| Decision Making | 1 | 2023 | 671 | 0.040 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 146 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 180 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2019 | 311 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2019 | 246 | 0.040 |
Why?
|
| Urban Health Services | 1 | 2017 | 44 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2018 | 118 | 0.030 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2017 | 22 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 30 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 125 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2016 | 21 | 0.030 |
Why?
|
| Mechanical Thrombolysis | 1 | 2016 | 16 | 0.030 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2016 | 14 | 0.030 |
Why?
|
| Morbidity | 1 | 2016 | 151 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 202 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2016 | 47 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 219 | 0.030 |
Why?
|
| Surgical Instruments | 1 | 2015 | 57 | 0.030 |
Why?
|
| Dominance, Cerebral | 1 | 2015 | 66 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2016 | 221 | 0.030 |
Why?
|
| Microcirculation | 1 | 2015 | 105 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2015 | 110 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 716 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 983 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1535 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 296 | 0.030 |
Why?
|
| Shear Strength | 1 | 2013 | 18 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1081 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 232 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2017 | 576 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 85 | 0.030 |
Why?
|
| Models, Cardiovascular | 1 | 2013 | 107 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 667 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2013 | 61 | 0.030 |
Why?
|
| Animals | 4 | 2020 | 27553 | 0.030 |
Why?
|
| Causality | 1 | 2013 | 80 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2013 | 253 | 0.030 |
Why?
|
| Software | 1 | 2017 | 668 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2013 | 128 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2013 | 176 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2013 | 53 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1075 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 842 | 0.030 |
Why?
|
| Magnetic Fields | 1 | 2012 | 11 | 0.030 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 1991 | 2 | 0.020 |
Why?
|
| Disinfectants | 1 | 1991 | 8 | 0.020 |
Why?
|
| Rhinovirus | 1 | 1991 | 25 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 303 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 161 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 187 | 0.020 |
Why?
|
| Air Microbiology | 1 | 1991 | 5 | 0.020 |
Why?
|
| Water Microbiology | 1 | 1991 | 14 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2013 | 127 | 0.020 |
Why?
|
| Pain | 1 | 2013 | 399 | 0.020 |
Why?
|
| Michigan | 1 | 2010 | 54 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2010 | 221 | 0.020 |
Why?
|
| Soaps | 1 | 1989 | 2 | 0.020 |
Why?
|
| Fresh Water | 1 | 1989 | 21 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 438 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 416 | 0.020 |
Why?
|
| Seasons | 1 | 1991 | 240 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 1136 | 0.020 |
Why?
|
| Medically Underserved Area | 1 | 2009 | 27 | 0.020 |
Why?
|
| Global Health | 1 | 1991 | 193 | 0.020 |
Why?
|
| Craniotomy | 1 | 2010 | 89 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2395 | 0.020 |
Why?
|
| Carotid Artery, External | 1 | 2009 | 8 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 662 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2009 | 32 | 0.020 |
Why?
|
| Accidents, Occupational | 1 | 2009 | 8 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2010 | 86 | 0.020 |
Why?
|
| Cavernous Sinus | 1 | 2009 | 15 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 956 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2010 | 125 | 0.020 |
Why?
|
| Deep Brain Stimulation | 1 | 2010 | 63 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 865 | 0.020 |
Why?
|
| Steel | 1 | 1988 | 1 | 0.020 |
Why?
|
| Conjunctivitis, Acute Hemorrhagic | 1 | 1988 | 1 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2010 | 682 | 0.020 |
Why?
|
| Enterovirus | 1 | 1988 | 34 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 201 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 847 | 0.020 |
Why?
|
| Feces | 1 | 1989 | 333 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1395 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2013 | 796 | 0.020 |
Why?
|
| Cell Line | 2 | 1988 | 2495 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2010 | 1496 | 0.020 |
Why?
|
| Radiology | 1 | 2009 | 202 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1930 | 0.020 |
Why?
|
| Skin | 1 | 1988 | 589 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2013 | 1063 | 0.010 |
Why?
|
| Prognosis | 1 | 2010 | 3800 | 0.010 |
Why?
|
| Humidity | 1 | 1988 | 91 | 0.000 |
Why?
|
| Temperature | 1 | 1988 | 409 | 0.000 |
Why?
|
| Models, Biological | 1 | 1988 | 1766 | 0.000 |
Why?
|